Killing Effect Of Sequential Herceptin And Doxorubicin Treatment On Breast Cancer Cell Line In Vitro

Background and objective:Biotherapy followed surgery, chemotherapy and radiotherapy is the fourth pattern in tumor therapy. Biochemotherapy is one of the developing prospective biotherapies, which combine biotherapy and chemotherapy is a firenew method of tumor treatment. Nowadays, some studies indicate HER-2/neu is overexpression in 20%～30% advanced breast cancers. The patients resist to chemotherapy and tamoxifen are not treated effectively. With the lucubrating of tumorigenesis and development of biotechnology, the HER-2/neu which contributes to tumor cells proliferation become a target of tumor treatment. Herceptin that targeted the HER-2/neu protein of the surface of the tumor cells is a humanized monoclonal antibody, and it was authorized by FDA in 1998. Now, it becomes one of the drugs of HER-2/neu-overexpressing advanced breast cancer treatment. But, the antineoplasmic activity is not mediated by cytotoxicity directly, the therapeutic effect is about 12%～ 24% when Herceptin is treated alone. So, a lot of clinical trials and clinical applications employ the combination of the Herceptin and chemotherapy. The experiment is to observe the killing effect of Herceptin and doxorubicin sequentially applied on breast cancer cell lines in vitro and to seek the optimal way of...